Amphastar Pharmaceuticals (AMPH) Operating Leases (2019 - 2026)

Amphastar Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $75.1 million for Q1 2026.

• On a quarterly basis, Operating Leases rose 84.59% year-over-year to $75.1 million in Q1 2026; TTM through Mar 2026 was $75.1 million, a 84.59% increase from a year earlier, with the FY2025 full-year figure at $37.7 million, down 10.02% from the prior year.
• Operating Leases improved to $75.1 million in Q1 2026 per AMPH's latest filing, from $37.7 million in the prior quarter.
• Across five years, Operating Leases topped out at $75.1 million in Q1 2026 and bottomed at $23.7 million in Q4 2022.
• The 5-year median for Operating Leases is $29.5 million (2024), against an average of $33.4 million.
• Across the five-year window, Operating Leases fell 10.02% in 2025 and surged 84.59% in 2026, its largest moves.
• Year by year, Operating Leases stood at $23.7 million in 2022, then advanced by 25.44% to $29.7 million in 2023, then jumped by 40.91% to $41.9 million in 2024, then fell by 10.02% to $37.7 million in 2025, then soared by 99.39% to $75.1 million in 2026.
• Per Business Quant, the three latest AMPH Operating Leases figures stand at $75.1 million (Q1 2026), $37.7 million (Q4 2025), and $39.4 million (Q3 2025).